BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 24661957)

  • 1. Fixed drug eruption due to etoricoxib in a patient with tolerance to celecoxib: the value of patch testing.
    Gómez de la Fuente E; Pampín Franco A; Caro Gutiérrez D; López Estebaranz JL
    Actas Dermosifiliogr; 2014 Apr; 105(3):314-5. PubMed ID: 24661957
    [No Abstract]   [Full Text] [Related]  

  • 2. Fixed drug eruption caused by etoricoxib with tolerance to celecoxib and parecoxib.
    Ponce V; Muñoz-Bellido F; Moreno E; Laffond E; González A; Dávila I
    Contact Dermatitis; 2012 Feb; 66(2):107-8. PubMed ID: 22233472
    [No Abstract]   [Full Text] [Related]  

  • 3. Fixed drug eruption caused by etoricoxib--2 cases confirmed by patch testing.
    Andrade P; Gonçalo M
    Contact Dermatitis; 2011 Feb; 64(2):118-20. PubMed ID: 21210830
    [No Abstract]   [Full Text] [Related]  

  • 4. Fixed drug eruption by etoricoxib confirmed by patch test.
    Sousa AS; Cardoso JC; Gouveia MP; Gameiro AR; Teixeira VB; Gonçalo M
    An Bras Dermatol; 2016; 91(5):652-654. PubMed ID: 27828643
    [TBL] [Abstract][Full Text] [Related]  

  • 5. COX-2 inhibitors in patients with sensitivity to nonselective NSAIDs.
    Cimbollek S; Quiralte J; Avila R
    N Engl J Med; 2009 Nov; 361(22):2197-8. PubMed ID: 19940308
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies.
    Bingham CO; Sebba AI; Rubin BR; Ruoff GE; Kremer J; Bird S; Smugar SS; Fitzgerald BJ; O'Brien K; Tershakovec AM
    Rheumatology (Oxford); 2007 Mar; 46(3):496-507. PubMed ID: 16936327
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Etoricoxib-induced acute generalized exanthematous pustulosis.
    Mäkelä L; Lammintausta K
    Acta Derm Venereol; 2008; 88(2):200-1. PubMed ID: 18311467
    [No Abstract]   [Full Text] [Related]  

  • 8. Cardiovascular risk associated with celecoxib or etoricoxib: a meta-analysis of randomized controlled trials which adopted comparison with placebo or naproxen.
    De Vecchis R; Baldi C; Di Biase G; Ariano C; Cioppa C; Giasi A; Valente L; Cantatrione S
    Minerva Cardioangiol; 2014 Dec; 62(6):437-48. PubMed ID: 25029569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Etoricoxib-induced erythema-multiforme-like eruption.
    Thirion L; Nikkels AF; Piérard GE
    Dermatology; 2008; 216(3):227-8. PubMed ID: 18182814
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fixed drug eruption and generalised erythema following etoricoxib.
    Augustine M; Sharma P; Stephen J; Jayaseelan E
    Indian J Dermatol Venereol Leprol; 2006; 72(4):307-9. PubMed ID: 16880582
    [No Abstract]   [Full Text] [Related]  

  • 11. Etoricoxib-induced fixed drug eruption with positive lesional patch tests.
    Calistru AM; Cunha AP; Nogueira A; Azevedo F
    Cutan Ocul Toxicol; 2011 Jun; 30(2):154-6. PubMed ID: 21108578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bullous fixed drug eruption induced by etoricoxib, confirmed by patch testing, with tolerance to celecoxib.
    Miroux-Catarino A; Silva L; Amaro C; Ferreira ML; Viana I
    Contact Dermatitis; 2019 Nov; 81(5):388-389. PubMed ID: 31215658
    [No Abstract]   [Full Text] [Related]  

  • 13. The use of etoricoxib and celecoxib for pain prevention after periodontal surgery: a double-masked, parallel-group, placebo-controlled, randomized clinical trial.
    Steffens JP; Santos FA; Pilatti GL
    J Periodontol; 2011 Sep; 82(9):1238-44. PubMed ID: 21235334
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Symmetrical Drug-Related Intertriginous and Flexural Exanthema (SDRIFE) Caused by Etoricoxib.
    Caralli ME; Seoane Rodríguez M; Rojas Pérez-Ezquerra P; Pelta Fernández R; De Barrio Fernández M
    J Investig Allergol Clin Immunol; 2016; 26(2):128-9. PubMed ID: 27164635
    [No Abstract]   [Full Text] [Related]  

  • 15. Early response to COX-2 inhibitors as a predictor of overall response in osteoarthritis: pooled results from two identical trials comparing etoricoxib, celecoxib and placebo.
    Bingham CO; Smugar SS; Wang H; Tershakovec AM
    Rheumatology (Oxford); 2009 Sep; 48(9):1122-7. PubMed ID: 19589894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multifocal fixed drug eruption due to celecoxib.
    Bellini V; Stingeni L; Lisi P
    Dermatitis; 2009; 20(3):174-6. PubMed ID: 19470306
    [No Abstract]   [Full Text] [Related]  

  • 17. Celecoxib-induced erythema multiforme-type drug eruption with a positive patch test.
    Arakawa Y; Nakai N; Katoh N
    J Dermatol; 2011 Dec; 38(12):1185-8. PubMed ID: 22103805
    [No Abstract]   [Full Text] [Related]  

  • 18. COX-2 inhibitor.
    Gøtzsche PC; Bjarnason NH
    Rheumatology (Oxford); 2007 Oct; 46(10):1623-4; author reply 1624-5. PubMed ID: 17726033
    [No Abstract]   [Full Text] [Related]  

  • 19. Coxibs: can this class of drugs survive?
    Tabrizchi R
    Vasc Health Risk Manag; 2005; 1(1):5-8. PubMed ID: 17319092
    [No Abstract]   [Full Text] [Related]  

  • 20. Etoricoxib-induced fixed drug eruption: Report of seven cases.
    Martínez Antón MD; Galán Gimeno C; Sánchez de Vicente J; Jáuregui Presa I; Gamboa Setién PM
    Contact Dermatitis; 2021 Mar; 84(3):192-195. PubMed ID: 32666601
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.